Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent shares of common stock, $0.0001 par value per share ("Common Stock") of Avenue Therapeutics, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 2,053,923 shares of Common Stock of the Issuer outstanding as of December 3, 2024, as disclosed in the Issuer's Form S-3 filed with the U.S. Securities and Exchange Commission (the "SEC") on December 4, 2024.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent shares of Common Stock of the Issuer held by the Fund and certain separate managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 2,053,923 shares of Common Stock of the Issuer outstanding as of December 3, 2024, as disclosed in the Issuer's Form S-3 filed with the SEC on December 4, 2024.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:02/14/2025
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:02/14/2025